GLP-1s
Semaglutide, tirzepatide, and retatrutide are three different receptor strategies — not three doses of the same drug. Each one answers the same question about hunger, fat, and lean mass in a different way.
Three compounds, three receptor strategies. Semaglutide activates GLP-1 alone — SELECT showed a 20% cardiovascular event reduction in obesity with established heart disease. Tirzepatide adds GIP and delivered 47% more weight loss than semaglutide in the head-to-head SURMOUNT-5 trial. Retatrutide adds glucagon on top, pushing the weight-loss ceiling higher and mobilizing liver fat directly, though it remains investigational. Pick by the outcome you need, not the headline number.
GLP-1s articles
Browse other categories:PeptidesProtocolsGuides
Compound Guides
SemaglutideOzempicWegovy
Semaglutide is the GLP-1 drug sold as Ozempic and Wegovy. Trial data show how dose and titration affect weight loss, blood sugar, side effects, and maintenance.
TirzepatideMounjaroZepbound
Tirzepatide activates GIP and GLP-1 receptors and is sold as Mounjaro and Zepbound. Trials show its effects on weight, blood sugar, side effects, and maintenance.
Read guideRetatrutideTriple-Agonist GLP-1
Retatrutide is an investigational triple agonist that produced large weight-loss and liver-fat reductions in trials. Dosing, side effects, and long-term use remain under study.
Read guideDeep Dives
Retatrutide Side EffectsDose, Titration, and Phenotype
Retatrutide side effects rise with dose and often cluster around titration. Phase 2 data cover gastrointestinal symptoms, skin sensitivity, heart rate, and serious events.
Retatrutide vs TirzepatideSame Receptors, Different Drug
Retatrutide and tirzepatide differ in receptor activity, trial status, appetite effects, liver-fat data, and side effects. No direct head-to-head trial exists.
Read guideGLP-1 FatigueWhy It Happens and What Helps
Fatigue during GLP-1 treatment can come from a steep calorie deficit, dehydration, low protein intake, or dose escalation. The pattern points to the most likely cause.
Read guideGLP-1s and Cholesterol
Semaglutide, tirzepatide, and retatrutide can lower triglycerides and liver fat, but their effects on LDL and HDL differ. Trial data show where each drug helps.
Read guideOral GLP-1 OptionsWegovy PillOrforglipron
Oral semaglutide is available for weight loss, while orforglipron remains in development. Compare efficacy, side effects, dosing rules, and likely access.
Read guideSupport Stacks for GLP-1sPreserving Lean Mass
Weight loss from semaglutide, tirzepatide, and retatrutide includes some lean mass. Trial data and practical measures clarify how to protect muscle and strength.
Read guideProtocols
Retatrutide + NAD+Critical Support Layer for GLP-1s
Retatrutide raises fat-oxidation demand. NAD+ supports beta-oxidation, energy stability, and fatigue resilience. PeptideFox research breaks down the evidence with a full protocol guide.
NAD+ and MOTS-c for EnergyThe Two-Compound Mito Stack
The NAD+ and MOTS-c stack supports the cellular adaptation loop that metabolic stress, GLP-1 use, and age can strain. PeptideFox research breaks down the evidence with a full dosing protocol and 12-week timeline.
Read guideRetatrutide: Advanced StackDual-Axis Protocol to Protect Lean Mass
Build muscle and lose fat — at the same time. Original research by PeptideFox for an advanced retatrutide body recomposition stack with MOTS-c and Tesamorelin along with NAD+ to support fat oxidation, training output, and lean-mass preservation.
Read guide